What intervention trials don’t tell us: the residual risk in primary prevention



A number of epidemiological studies and intervention clinical trials demonstrated that the in spite of the achievement of recommended targets of low-density lipoprotein (LDL)-cholesterol in subjects not yet affected by cardiovascular diseases, a substantial percentage of them still remain at risk of acute events. Beyond LDL-c, additional abnormalities of lipid profile, consisting of low high-density lipoprotein (HDL)-cholesterol and high levels of triglycerides or the combination of the two, may play a role in determining the cardiovascular prognosis. The mentioned lipid abnormalities, together with elevated apolipoprotein B and non-HDL cholesterol, do represent the burden of the so-called residual cardiovascular risk of lipid nature. Although it is plausible that there is benefit in normalizing lipid abnormalities other than LDL-C in primary prevention, it is still controversial that this actually reduces clinical events. Recent attempts to further reduce the risk of patients already given statin therapy with drugs raising HDL-c or lowering triglycerides levels failed to demonstrate a favorable impact on secondary prevention. Of importance, evidence is completely lacking for people at lower risk such as those requiring primary prevention. New and more safe/effective drugs are currently under investigation in this field. Until further information is available on the efficacy and safety of interventions aimed at restoring normal levels of triglycerides and HDL, we have to continue to implement safe and effective methods we already have to blunt the cardiovascular risk, consisting mainly of lifestyle changes and statin therapy.


Residual risk Cardiovascular events Lipids HDL Triglycerides 


Conflict of interest



  1. 1.
    Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, Kadowaki T, Lablanche JM, Marx N, Plutzky J, Reiner Z, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P (2008) The Residual risk reduction initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 102(10 Suppl):1K–34KPubMedCrossRefGoogle Scholar
  2. 2.
    Arcelus JI (2009) Current status of venous thromboembolism prophylaxis. Surg Technol Int 18:55–62PubMedGoogle Scholar
  3. 3.
    Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Borén J, Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A, Watts GF, for the European Atherosclerosis Society Consensus Panel (2011) Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 32:1345–1361PubMedCrossRefGoogle Scholar
  4. 4.
    Ghandehari H, Kamal-Bahl S, Wong ND (2008) Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003–2004. Am Heart J 156:112–119PubMedCrossRefGoogle Scholar
  5. 5.
    Rouvre M, Vol S, Gusto G, Born C, Lantieri O, Tichet J, Lecomte P (2011) Low high density lipoprotein cholesterol: prevalence and associated risk-factors in alarge French population. Ann Epidemiol 21(2):118–127PubMedCrossRefGoogle Scholar
  6. 6.
    Ferrières J, Bérard E, Crisan O, Bongard V (2010) Residual dyslipidaemia after statin treatment in France: prevalence and risk distribution. Arch Cardiovasc Dis 103:302–309PubMedCrossRefGoogle Scholar
  7. 7.
    Bestehorn K, Smolka W, Pittrow D, Schulte H, Assmann G (2010) Atherogenic dyslipidemia as evidenced by the lipid triad: prevalence and associated risk in statin-treated patients in ambulatory care. Curr Med Res Opin 26:2833–2839PubMedCrossRefGoogle Scholar
  8. 8.
    Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W, Atherosclerosis Risk in Communities Study Group (2001) Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 104:1108–1113PubMedCrossRefGoogle Scholar
  9. 9.
    Emerging Risk Factors Collaboration (2009) Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302:1993–2000CrossRefGoogle Scholar
  10. 10.
    Nordestgaard BG, Benn M, Schnohr P, Tybjærg-Hansen A (2007) Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298:299–308PubMedCrossRefGoogle Scholar
  11. 11.
    Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM (2007) Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 298:309–316PubMedCrossRefGoogle Scholar
  12. 12.
    Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt SM, Khaw KT, Gudnason V (2007) Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 115:450–458PubMedCrossRefGoogle Scholar
  13. 13.
    Freiberg JJ, Tybjærg-Hansen A, Jensen JS, Nordestgaard BG (2008) Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 300:2142–2152PubMedCrossRefGoogle Scholar
  14. 14.
    Hokanson JE, Austin MA (1996) Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3:213–219PubMedCrossRefGoogle Scholar
  15. 15.
    Asia Pacific Cohort Studies Collaboration (2004) Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation 110:2678–2686CrossRefGoogle Scholar
  16. 16.
    Briel M, Ferreira-Gonzalez I, You JJ, Karanicolas PJ, Akl EA, Wu P, Blechacz B, Bassler D, Wei X, Sharman A, Whitt I, Alves da Silva S, Khalid Z, Nordmann AJ, Zhou Q, Walter SD, Vale N, Bhatnagar N, O’Regan C, Mills EJ, Bucher HC, Montori VM, Guyatt GH (2009) Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 338:b92PubMedCrossRefGoogle Scholar
  17. 17.
    Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376:1670–1681PubMedCrossRefGoogle Scholar
  18. 18.
    Jafri H, Alsheikh-Ali AA, Karas RH (2010) Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann Intern Med 153:800–808PubMedGoogle Scholar
  19. 19.
    Ridker PM, Genest J, Boekholdt SM, Libby P, Gotto AM, Nordestgaard BG, Mora S, MacFadyen JG, Glynn RJ, Kastelein JJ, JUPITER Trial Study Group (2010) HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet 376:333–339PubMedCrossRefGoogle Scholar
  20. 20.
    van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, Stroes ES, Tikkanen MJ, Wareham NJ, Faergeman O, Olsson AG, Pedersen TR, Khaw KT, Kastelein JJ (2008) High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A–I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol 51:634–642PubMedCrossRefGoogle Scholar
  21. 21.
    Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ (2011) Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364:127–135PubMedCrossRefGoogle Scholar
  22. 22.
    Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, Grobbee DE, Cass A, Chalmers J, Perkovic V (2010) Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 375(9729):1875–1884PubMedCrossRefGoogle Scholar
  23. 23.
    ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP (2010) Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362:1563–1574PubMedCrossRefGoogle Scholar
  24. 24.
    Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B, ILLUMINATE Investigators (2007) Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357:2109–2122PubMedCrossRefGoogle Scholar
  25. 25.
    Villines TC, Stanek EJ, Devine PJ, Turco M, Miller M, Weissman NJ, Griffen L, Taylor AJ (2010) The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol 55:2721–2726PubMedCrossRefGoogle Scholar
  26. 26.
    Bruckert E, Labreuche J, Amarenco P (2010) Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 210:353–361PubMedCrossRefGoogle Scholar
  27. 27.
    Holman RR, Paul S, Farmer A, Tucker L, Stratton IM, Neil HA, Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes Study Group (2009) Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial. Diabetologia 52:50–59PubMedCrossRefGoogle Scholar
  28. 28.
    Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J, ASCOT investigators (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361:1149–1158PubMedCrossRefGoogle Scholar
  29. 29.
    Kodama S, Tanaka S, Saito K, Shu M, Sone Y, Onitake F, Suzuki E, Shimano H, Yamamoto S, Kondo K, Ohashi Y, Yamada N, Sone H (2007) Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: a meta-analysis. Arch Intern Med 167:999–1008PubMedCrossRefGoogle Scholar
  30. 30.
    Magkos F, Tsekouras YE, Prentzas KI, Basioukas KN, Matsama SG, Yanni AE, Kavouras SA, Sidossis LS (2008) Acute exercise-induced changes in basalVLDL-triglyceride kinetics leading to hypotriglyceridemia manifest more readily after resistance than endurance exercise. J Appl Physiol 105:1228–1236PubMedCrossRefGoogle Scholar
  31. 31.
    Maeda K, Noguchi Y, Fukui T (2003) The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis. Prev Med 37:283–290PubMedCrossRefGoogle Scholar
  32. 32.
    Koenig W, Ridker PM (2011) Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk ≥5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities. Eur Heart J 32:75–83PubMedCrossRefGoogle Scholar

Copyright information

© SIMI 2011

Authors and Affiliations

  1. 1.Department of MedicineVimercate Hospital, Azienda Ospedaliera di Desio e Vimercate (Monza-Brianza)Vimercate (MB)Italy

Personalised recommendations